How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

@article{DiamantiKandarakis1998HowAI,
  title={How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?},
  author={Evanthia Diamanti-Kandarakis},
  journal={Journal of Endocrinological Investigation},
  year={1998},
  volume={21},
  pages={623-629}
}

Polycystic Ovary Syndrome and Hyperandrogenic States

Androgen receptor mediated activity in the ovary : implications for Polycystic Ovary Syndrome

S ARISING FROM THIS THESIS

Spironolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile

The data show that long-term treatment with spironolactone exerts no negative effects on lipoprotein profile and glucose metabolism; more relevant beneficial effects on glucose and lipid metabolism were observed when the antiandrogen was associated with weight loss in overweight PCOS women.

References

SHOWING 1-10 OF 53 REFERENCES

One‐Year Experience in the Treatment of Benign Prostatic Hyperplasia with Finasteride

It is concluded that finasteride has the potential to be an effective chronic therapy for benign prostatic hyperplasia and can reduce prostate size and improve maximum urinary flow with no loss of efficacy after 1 year of treatment.

ORAL PROGESTATIONAL ACTIVITY OF SPIRONOLACTONE1

Data from this study are consistent with the menstrual irregularity and amenorrhea seen in women during treatment with spironolactone.

REVIEW ARTICLE: THE POLYCYSTIC OVARY SYNDROME

Current evidence regarding the basis for the dysfunction of ovarian steroidogenesis and follicular maturation, and the aberration of gonadotropin secretion as related to the inappropriate steroid feedback system will be reviewed.

The use of human skin fibroblasts to obtain potency estimates of drug binding to androgen receptors.

  • C. EilS. Edelson
  • Biology, Medicine
    The Journal of clinical endocrinology and metabolism
  • 1984
Spironolactone, which is rapidly metabolized in vivo to a much less potent competitor, is the most potent antiandrogen in its ability to interact in vitro with human skin fibroblast androgen receptors; estradiol is a relatively potent androgen receptor binder; and this receptor assay should be useful in selecting drugs for androgen and anti androgen therapy.

THE EFFECT OF SPIRONOLACTONE ON HIRSUTISM AND FEMALE ANDROGEN METABOLISM

Although spironolactone was not consistently successful, it may represent effective therapy for a sub group of patients with hirsutism and there was subjective benefit in hair growth and greasiness and a significant reduction in the semi‐objective Ferriman‐Gallwey index.

The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women.

Antiandrogen treatment partially reversed the peripheral insulin resistance associated with hyperandrogenism regardless of which antiandrogen was used, suggesting that in women, androgen excess per se contributes to impairment of insulin action.
...